Conical-PEP is safe, reduces lung hyperinflation and contributes to improved exercise endurance in patients with COPD: a randomised cross-over trial
Tadsawiya Padkao, Watchara Boonsawat and Chulee U Jones
Khon KaenQuestion
: Does a new positive expiratory pressure device (conical-PEP) decrease lung hyperinflation during exercise in patients with chronic obstructive pulmonary disease compared to normal breathing? Does it increase the duration of exercise?Design
Outcome measures: Total lung capacity (inspiratory capacity and slow vital capacity), breathlessness, and leg discomfort were measured pre and post exercise. Cardiorespiratory function was measured pre and during the last 30 s of exercise. Duration of exercise was recorded.
Results:After the experimental intervention, inspiratory capacity increased 200 ml (95% CI 0 to 400) and slow vital capacity increased 200 ml (95% CI 0 to 400) more than the control intervention. Participants exercised for 107 s (95% CI –23 to 238) more during the experimental intervention than the control intervention. Conical-PEP breathing during exercise resulted in 6.1 fewer breaths/
: The novel conical-PEP device decreases lung hyperinflation, is safe to use, and tends to increase the duration of exercise.
: A randomised, cross-over trial with concealed allocation. Participants: Thirteen patients with moderate to severe chronic obstructive pulmonary disease (mean FEV1 61% predicted). Intervention: The experimental intervention was conical-PEP breathing with a positive expiratory pressure of 4–20 cmH2O during 30% of 1 RM alternate knee extension exercise at 70% age-predicted HRmax to fatigue. The control intervention was normal breathing.
min (95% CI 1.4 to 10.8) than normal breathing; it did not have any adverse effects on CO
2 retention or oxygen saturation.Conclusion
Trial registration: NCT00741832. [Padkao T, Boonsawat W, Jones CU (2010) Conical-PEP is safe, reducesJournal of Physiotherapy 56: 33–39]
lung hyperinflation and contributes to improved exercise endurance in patients with COPD: a randomised cross-over
trial.
Nao tenho seu e-mail por isso to colocando o link desses 2 trabalhos. Apesar de nao serem perfeitos nem ligados ao assunto do Post , mostram um tendencia.
ResponderExcluirhttp://www.ncbi.nlm.nih.gov/pubmed/21358492
http://chiromt.com/content/pdf/1746-1340-18-3.pdf
vou postando mais com o tempo
Abraco
Jonas Marques